Clinical Trial Update: Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC) [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging study completed assessing SP-333 for opioid-induced constipation (OIC), evaluating safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid-induced Constipation

Drugs mentioned

• SP-333

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Constipation | Phase 2 | Status: COMPLETED